देश: ऑस्ट्रेलिया
भाषा: अंग्रेज़ी
स्रोत: Department of Health (Therapeutic Goods Administration)
tranexamic acid
Pfizer Australia Pty Ltd
Tranexamic acid
Registered
HOSPIRA™ TRANEXAMIC ACID INJECTION Tranexamic Acid CONSUMER MEDICINE INFORMATION_ _ _Date of Dispensing _ _Consumer Name _ _Pharmacist Name _ _Consumer Address _ _Pharmacist Address _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about HOSPIRA™ Tranexamic Acid Injection. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you receiving HOSPIRA™ Tranexamic Acid Injection against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT HAVING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET You may need to read it again. WHAT HOSPIRA™ TRANEXAMIC ACID INJECTION IS USED FOR HOSPIRA™ Tranexamic Acid Injection is used to reduce bleeding and the need for blood transfusion in adults and children undergoing heart surgery, and adults undergoing total knee or hip replacement surgery. It works by slowing the breakdown of blood clots. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. This medicine is not addictive. BEFORE YOU ARE GIVEN HOSPIRA™ TRANEXAMIC ACID INJECTION _WHEN YOU MUST NOT BE GIVEN _ _IT _ YOU MUST NOT BE GIVEN HOSPIRA™ TRANEXAMIC ACID INJECTION IF YOU • have an allergy to tranexamic acid Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing • swelling of the face, lips, tongue or other parts of the body • rash, itching or hives on the skin. YOU MUST NOT BE GIVEN IT IF • you have a problem with colour vision that developed after you were born • you have problems associated with blood clots or stroke. _BEFORE YOU ARE GIVEN IT_ TELL YOUR DOCTOR IF YOU HAVE OR HAVE HAD ANY OF THE FOLLOWING • kidney problems • convulsions, fits or seizures. • you, or someone in your family has ever suffered from stroke or blood clots TELL YOUR पूरा दस्तावेज़ पढ़ें
HOSPIRA™ TRANEXAMIC ACID INJECTION NAME OF THE MEDICINE Tranexamic acid The chemical structure of tranexamic acid is: Chemical name: trans-4-(aminomethyl) cyclohexane-carboxylic acid. The molecular formula of tranexamic acid is C 8 H 15 NO 2 and its molecular weight is 157.2. The CAS number for tranexamic acid is 1197-18-8. DESCRIPTION Tranexamic acid is a white crystalline powder that is odourless or almost odourless. It is freely soluble in water and in glacial acetic acid, practically insoluble in methanol, ethanol, acetone, diethyl ether and benzene. Hospira™ Tranexamic Acid Injection is a sterile, clear, colourless solution. The pH is 6.5 to 8.0. Each 5 mL ampoule of Hospira™ Tranexamic Acid Injection contains 500 mg tranexamic acid, made up to 5 mL with Water for Injections (as the inactive ingredient). Each 10 mL ampoule of Hospira™ Tranexamic Acid Injection contains 1000 mg tranexamic acid, made up to 10 mL with Water for Injections (as the inactive ingredient). PHARMACOLOGY PHARMACODYNAMICS Tranexamic acid is a competitive inhibitor of plasminogen activation and at much higher concentrations a noncompetitive inhibitor of plasmin, thus implying that tranexamic acid interferes with the fibrinolytic process in the same way as aminocaproic acid. Tranexamic acid is about 10 times more potent _in vitro_ than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Version 1.0 Page 1 of 27 Tranexamic acid in a concentration of 1 mg/mL does not aggregate platelets _in vitro_ . Tranexamic acid in concentrations up to 10 mg/mL blood has no influence on the platelet count, the coagulation time or various coagulation factors in whole blood or citrated blood in normal subjects. On the other hand tranexamic acid in concentrations of 1 mg/mL and 10 mg/mL blood prolongs the thrombin time. Clinical pharmacodynamics data that examined the _in vivo_ effect o पूरा दस्तावेज़ पढ़ें